Abstract:4701 Introduction : Inflammatory breast carcinoma (IBC), a particularly aggressive orphan cancer accounts for 1-6% of all invasive breast tumors with rather poor prognosis. The ability to characterize IBC based on molecular signatures will greatly facilitate the rational development of novel therapeutic strategies targeting key signaling pathways involved in growth/survival of IBC cells. RhoC GTPase, a member of the Ras superfamily of small GTPases, has been reported to be overexpressed in 90% of IBC tumors versus 38% of stage matched, non-IBC tumors. The enzyme, isoprenylcysteine carboxyl methyltransferase (Icmt) involved in prenylation of the Ras superfamily proteins plays a critical role in oncogenic transformation. Previous published studies in colon cancer cells have shown that treatment with a novel small molecule inhibitor (cysmethynil) targeting Icmt resulted in mislocalization of Ras, inhibition of anchorage independent growth, and impaired epidermal growth factor signaling. Therefore, the objectives of this study are 1. Characterize IBC cell lines and establish an imageable IBC tumor model to identify critical dysregulated pathways 2. Characterization of a small GTPases-specific small molecule inhibitor in the IBC models. Results: The growth kinetics in serum and serum-free media have been optimized for the various human SUM IBC cell lines. Further the SUM 149 and 159 cell lines have been established to express luciferase reporter gene driven by a constitutive CMV promoter. Retrovirus-packaging cell line Psi-X-Ampho were transfected with luciferase-reporter plasmid by the use of Lipofectamine reagent for the packaging of replication-deficient retrovirus. The infected SUM cells were selected for the expression of the desired luciferase gene by adding puromycin in cell culture medium. The Icmt small molecule inhibitor, cysmethynil, is being tested in the parent and luciferase expressing SUM cell lines and compared with non-IBC cell lines. Preliminary studies reveal a dose- and time-dependent inhibition of IBC cell proliferation in the presence of cysmethynil, as assessed by MTT assays. Immunoblot analysis of the cell lysates revealed a specific downregulation of Rho proteins on day 4 post cysmethynil treatment. Conclusion: Currently, in addition to understanding the mechanism of Rho inhibition in the IBC cells, we are also generating other imageable IBC cell lines. There are few IBC models and these luciferase cell lines will be extremely useful not only for characterization and exploration of the molecular signatures of human IBC but also for quantitative analysis and in vivo non-invasive imaging in tumor models.

Inflammatory Breast Cancer (IBC): Clues for Targeted Therapies.

Inflammatory breast cancer: novel preoperative therapies

Inflammatory breast cancer biology: the tumour microenvironment is key

Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer

Development of Cellular Models and Small Gtpases-Targeted Therapeutics for Inflammatory Breast Cancer

Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy

Clinically Relevant Inflammatory Breast Cancer Patient-Derived Xenograft-Derived Ex Vivo Model for Evaluation of Tumor-Specific Therapies

Inflammatory breast cancer biomarkers and biology

Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model

Clinicogenomic characterization of inflammatory breast cancer

High endogenous CCL2 expression promotes the aggressive phenotype of human inflammatory breast cancer

Genomic and Transcriptomic Profiling of Inflammatory Breast Cancer Reveals Distinct Molecular Characteristics to Non-Inflammatory Breast Cancers

Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors

Characterization of the Immune Microenvironment in Inflammatory Breast Cancer Using Multiplex Immunofluorescence

Inflammatory breast cancer: An overview about the histo-pathological aspect and diagnosis

Integrated Analyses of DNA Copy Number Variations and Gene Expression in Inflammatory Breast Cancer (IBC).

The tumor microenvironment and inflammatory breast cancer

[Systemic treatments of inflammatory breast cancer: an overview]

Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer

Genomic and Transcriptomic Profiling of Inflammatory Breast Cancers and Noninflammatory Breast Cancers in Asian Women.

In Vitro Vascularized Tumor Platform for Modeling Tumor-Vasculature Interactions of Inflammatory Breast Cancer